Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more
Psyence Biomedical Ltd. Common Shares (PBM) - Total Liabilities
Latest total liabilities as of September 2025: $943.07K USD
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has total liabilities worth $943.07K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Psyence Biomedical Ltd. Common Shares - Total Liabilities Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Psyence Biomedical Ltd. Common Shares Competitors by Total Liabilities
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
India | ₹7.39 Billion |
|
CTS EVENTIM
BE:EVD
|
Germany | €2.28 Billion |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
Malaysia | RM551.00K |
|
CORP. FIN. ALBA - Dusseldorf Stock Exchang
DU:CSV
|
Germany | €603.50 Million |
|
O REILLY AUTO - Dusseldorf Stock Exchang
DU:OM6
|
Germany | €15.98 Billion |
|
Labrador Technologies Inc
V:LTX
|
Canada | CA$1.17 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Psyence Biomedical Ltd. Common Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Psyence Biomedical Ltd. Common Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual total liabilities of Psyence Biomedical Ltd. Common Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $594.37K | -95.09% |
| 2024-03-31 | $12.10 Million | -15.18% |
| 2023-03-31 | $14.27 Million | -12.87% |
| 2022-03-31 | $16.38 Million | +16104.79% |
| 2021-03-31 | $101.08K | -- |